Boston, MA -- (SBWIRE) -- 06/18/2013 -- Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults and is associated with a histologic and/or radiologic pattern of usual interstitial pneumonia (NHLBI, 2011; Raghu et al., 2011). As a fatal disease that falls under the umbrella of interstitial lung disease of unknown cause, IPF is limited to the lungs and manifests with irreversible and variable scarring, stiffening, and thickening of the lung tissues that leads to progressively worsening of pulmonary function (NHLBI, 2011; Raghu et al. 2011). IPF is the most common form of idiopathic interstitial pneumonia and also has the worst prognosis, with only three to five years of median survival (Olson and Swigris, 2012). Respiratory failure accounts for over 80% of IPF fatalities (Raghu et al., 2006). IPF is more common in men, and its prevalence typically increases with advancing age.

View Full Report Details and Table of Contents

GlobalData forecasts that there will be 45,718 incident cases of IPF in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK) in 2022, with an Annual Growth Rate (AGR) of 2.01% during 2012-2022. By 2022, there will be 88,357 prevalent cases of IPF in the 6MM. Changes in the population structure and population growth will be the major drivers of the observed increase in the incident and prevalent cases of IPF. In addition to population growth, further industrialization or other circumstances that could increase exposure to potential risk factors for the disease could also drive the increase in the incident and prevalent cases of IPF. The emergence of new evidence and a better understanding of the pathogenesis and biology of IPF will possibly help in detecting IPF in the preclinical and early stages and in improving treatment, outcomes, and prognosis.

Scope

- The Idiopathic Pulmonary Fibrosis (IPF) EpiCast Report provides an overview of the risk factors and global trends of IPF in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK).
- It includes a 10-year epidemiology forecast of the incident and prevalent cases of IPF segmented by sex and age (by five-year increments, beginning at age 50 years and ending at age 85 years and older) in the 6MM.

Reasons to Get This Report

- Develop business strategies by understanding the trends shaping and driving the global IPF market.
- Quantify patient populations in the global IPF market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for IPF therapeutics in each of the markets covered.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022
- Idiopathic Pulmonary Fibrosis Global Clinical Trials Review, H2, 2012
- EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US - Epidemiology Forecast to 2022
- EpiCast Report: Psoriasis - Epidemiology Forecast to 2022
- EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
- EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022
- EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022
- EpiCast Report: Dermatophytic Onychomycosis - Epidemiology Forecast to 2022
- EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022
- EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022